Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drug Dosing: Geriatric Patients

Drug Dosing: Geriatric Patients

Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...

Pharmacodynamics in Geriatric Patients: Effects of Age

Pharmacodynamics in Geriatric Patients: Effects of Age

Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...

Parkinson's Disease: Treatment

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion

In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

[The European Society for Clinical Nutrition and Metabolism (ESPEN) Guideline on Clinical Nutrition and Hydration in Geriatrics].

Revista espanola de geriatria y gerontologia·2026

Same author

[The European Society for Clinical Nutrition and Metabolism (ESPEN) Guideline on Clinical Nutrition and Hydration in Geriatrics].

Nutricion hospitalaria·2026

Same author

Psychiatry meets neurodegeneration - A collaborative approach to dementia prevention.

The journal of prevention of Alzheimer's disease·2025

Same author

Pre-psychosis in later life as a risk factor for progressive cognitive decline: Findings from the IPA psychosis in neurodegenerative disease working group.

International psychogeriatrics·2025

Same author

[ESPEN guideline on clinical nutrition and hydration in geriatrics].

Geriatrie et psychologie neuropsychiatrie du vieillissement·2025

Same author

Digital phenotyping of social functioning and employment in people with schizophrenia: Pilot data from an international sample.

Psychiatry and clinical neurosciences·2025

Search research articles

Related Experiment Video

Updated: Jul 18, 2026

Self-Administration of Drugs in Mouse Models of Feeding and Obesity

Self-Administration of Drugs in Mouse Models of Feeding and Obesity

Published on: June 8, 2021

Mortality in elderly dementia patients treated with risperidone.

Martin Haupt¹, Alfonso Cruz-Jentoft, Dilip Jeste

¹Department of Cognitive Disorders, Neurologic Research Institute, Neuro-Centrum Düsseldorf, Düsseldorf, Germany. m.haupt@alzheimer-praxis-duesseldorf.de

Journal of Clinical Psychopharmacology

|November 18, 2006

Summary

This study found a nonsignificant increase in mortality for dementia patients treated with risperidone compared to placebo. Careful risk-benefit assessments are crucial before prescribing this antipsychotic for behavioral symptoms.

Related Experiment Videos

Last Updated: Jul 18, 2026

Self-Administration of Drugs in Mouse Models of Feeding and Obesity

Self-Administration of Drugs in Mouse Models of Feeding and Obesity

Published on: June 8, 2021

Area of Science:

Geriatric Medicine
Psychopharmacology
Clinical Trials

Background:

Behavioral and psychological symptoms of dementia (BPSD), including agitation and psychosis, significantly impact patient and caregiver well-being.
Atypical antipsychotics are commonly used for BPSD, but concerns exist regarding increased mortality.
A US FDA warning followed a meta-analysis showing increased mortality with atypical antipsychotics in dementia patients.

Purpose of the Study:

To specifically evaluate the mortality risk associated with risperidone in dementia patients.
To analyze data from placebo-controlled trials to compare risperidone's safety profile.

Main Methods:

A meta-analysis of 6 phase-2/3 double-blind trials comparing risperidone and placebo in 1721 dementia patients.
Calculation of hazard ratios and 95% confidence intervals to assess relative mortality risk.
Data sourced from Johnson & Johnson Pharmaceutical Research and Development.

Main Results:

Mortality was 4.0% with risperidone versus 3.1% with placebo (relative risk: 1.21; 95% CI: 0.71-2.06).
The increase in mortality was not statistically significant.
Common causes of death included pneumonia, cardiac events, and cerebrovascular disorders; no dose-mortality relationship was observed.

Conclusions:

This meta-analysis indicates a nonsignificant increase in mortality during risperidone treatment for dementia patients.
Larger studies are needed to definitively rule out a small mortality risk.
Prescribing risperidone for BPSD requires careful consideration of potential benefits versus risks.